<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03505710</url>
  </required_header>
  <id_info>
    <org_study_id>DS8201-A-U204</org_study_id>
    <secondary_id>2017-004781-94</secondary_id>
    <secondary_id>JapicCTI-183916</secondary_id>
    <nct_id>NCT03505710</nct_id>
  </id_info>
  <brief_title>DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer</brief_title>
  <acronym>DESTINY-Lung01</acronym>
  <official_title>A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non Small Cell Lung Cancer (NSCLC) (DESTINY-Lung01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to evaluate the efficacy of trastuzumab deruxtecan in&#xD;
      HER2-overexpressing and/or HER2-mutated advanced NSCLC participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 21, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">May 3, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR) of trastuzumab deruxtecan (DS-8201a) assessed by independent central review (ICR)</measure>
    <time_frame>within 30 months</time_frame>
    <description>ORR is assessed for each cohort by ICR, based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) of trastuzumab deruxtecan (DS-8201a) assessed by investigator</measure>
    <time_frame>within 30 months</time_frame>
    <description>ORR is assessed for each cohort by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>within 30 months</time_frame>
    <description>Assessment categories: Investigator, ICR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>within 30 months</time_frame>
    <description>Assessment categories: Investigator, ICR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>until the end of the trial, including 40-day follow-up visit, followed by long-term follow-up visits until death, withdrawal of consent, loss to follow-up, or study closure, whichever occurs first (within approximately 30 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1: HER2 Overexpressing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 will enroll participants with HER2-overexpressing(immunohistochemistry [IHC] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma to receive 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1a: HER2 Overexpressing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1a will enroll participants with HER2-overexpressing (immunohistochemistry [IHC] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma to receive 5.4 mg/kg trastuzumab deruxtecan (DS-8201a).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: HER2 Mutated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2 will enroll participants with HER2-mutated, unresectable and/or metastatic NSCLC to receive 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab deruxtecan (DS-8201a)</intervention_name>
    <description>The investigational product is a sterile lyophilized powder, which is made into solution for intravenous administration.</description>
    <arm_group_label>Cohort 1: HER2 Overexpressing</arm_group_label>
    <arm_group_label>Cohort 1a: HER2 Overexpressing</arm_group_label>
    <arm_group_label>Cohort 2: HER2 Mutated</arm_group_label>
    <other_name>DS-8201a</other_name>
    <other_name>Experimental product</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥20 years old in Japan, ≥18 years old in other countries&#xD;
&#xD;
          -  Pathologically documented unresectable and/or metastatic non-squamous NSCLC&#xD;
&#xD;
          -  Has relapsed from or is refractory to standard treatment or for which no standard&#xD;
             treatment is available&#xD;
&#xD;
          -  For Cohort 1 and Cohort 1a: HER2-overexpression (IHC 2+ or 3+) status must be assessed&#xD;
             and confirmed by Clinical Laboratory Improvement Amendments (CLIA)-certified&#xD;
             laboratory or equivalent, from an archival tumor tissue sample&#xD;
&#xD;
          -  For Cohort 2 only: Participant has any known documented activating HER2 mutation from&#xD;
             an archival tumor tissue sample analyzed by CLIA laboratory or equivalent. Note: HER2&#xD;
             mutation documented only from a liquid biopsy sample cannot be used for enrollment.&#xD;
&#xD;
          -  Presence of at least 1 measurable lesion assessed by the investigator and based on&#xD;
             Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1&#xD;
&#xD;
          -  Is willing and able to provide an adequate archival tumor tissue sample&#xD;
&#xD;
          -  Is willing to undergo a tissue biopsy, after the completion of the most recent&#xD;
             treatment regimen&#xD;
&#xD;
          -  Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Had been previously treated with HER2-targeted therapies, except for pan-HER class&#xD;
             tyrosine kinase inhibitors&#xD;
&#xD;
          -  For Cohort 1 and Cohort 1a: Has known HER2 mutation&#xD;
&#xD;
          -  Has a medical history of myocardial infarction, symptomatic congestive heart failure&#xD;
             (CHF) (NYHA classes II-IV), unstable angina or serious cardiac arrhythmia&#xD;
&#xD;
          -  Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that&#xD;
             required steroids, or current ILD/pneumonitis, or suspected ILD/pneumonitis that&#xD;
             cannot be ruled out due to imaging at screening&#xD;
&#xD;
          -  Has a QT interval corrected by Fridericia's formula (QTcF) prolongation to &gt; 450&#xD;
             millisecond (ms) in males and &gt; 470 ms in females&#xD;
&#xD;
          -  Has a medical history of clinically significant lung disease&#xD;
&#xD;
          -  Is suspected to have certain other protocol-defined diseases based on imaging at&#xD;
             screening period&#xD;
&#xD;
          -  Has history of any disease, metastatic condition, drug/medication use or other&#xD;
             condition that might, per protocol or in the opinion of the investigator, compromise:&#xD;
&#xD;
               1. safety or well-being of the participant or offspring&#xD;
&#xD;
               2. safety of study staff&#xD;
&#xD;
               3. analysis of results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Team Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego (UCSD)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-1503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine at St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065-6007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>ile-de-France</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <state>Rhne</state>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord - CHU Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>12915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Larrey, CHU-Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Ōsaka-sayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Nagaizumi</city>
        <state>Sunto-gun</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo Ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>April 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2 over-expression</keyword>
  <keyword>HER2 mutation</keyword>
  <keyword>Unresectable or metastatic</keyword>
  <keyword>Non-squamous</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Immunoconjugates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/daiichi-sankyo/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

